17 November 2026

Radspherin[®] shows favorable safety profile in the first interim safety readout from the ongoing randomized phase 2 trial in ovarian cancer

Oslo, Norway, 17 November 2026: Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that no serious adverse event was related to Radspherin® in the interim safety analysis of its ongoing randomized Phase 2 trial (RAD-18-003, NCT06504147) in patients with peritoneal metastases from advanced ovarian cancer. These are the first randomized, controlled safety data for Radspherin®.

As of the data cut-off on 30 October 2026, 74 patients had been randomized (2:1 – Radspherin® : Control). The safety analysis set comprised 56 primary ovarian cancer patients who achieved complete surgical resection after neoadjuvant chemotherapy, of whom 40 received a single intraperitoneal dose of Radspherin® (7 MBq) after surgery in addition to standard of care, and 16 received standard of care alone.

At this stage in the trial, there were no serious adverse events considered related to Radspherin®, no deaths, and no adverse events leading to discontinuation. The proportion of patients with treatment-emergent adverse events (TEAEs, events reported on or after treatment start, regardless of cause) was similar in both arms. The safety profile of Radspherin® remains consistent with previously published clinical data.

The majority of TEAEs in the experimental arm were considered unrelated to Radspherin® and were consistent with the underlying disease and expected postoperative clinical course. At the patient level, the most frequent TEAEs in the experimental arm were constipation, anemia, abdominal pain, nausea and hypokalemia. A total of 10 events reported in five patients (12.5%) were considered as possibly related to Radspherin®. These latter events were all mild or moderate (Grade 1 or 2) and included vomiting (2), nausea, abdominal pain, constipation, headache, dizziness, fatigue, anemia, and decreased lymphocyte count (one event each).

The trial’s Independent Data Monitoring Committee reviewed the unblinded safety data on 13 November 2026 and recommended that the trial continue without modification.

“Women in this trial have just been through neoadjuvant chemotherapy and major abdominal surgery, so any treatment added afterwards must be well tolerated,” said Professor Ignace Vergote, gynaecologic oncologist and Professor Emeritus at the Catholic University Leuven, Belgium. “It is encouraging to now see this in randomized data. The adverse events observed in both arms of the trial are what we would expect in patients recovering from this type of surgery, which is reassuring for patients and their physicians.”

These randomized data are consistent with the safety profile seen in previous Radspherin® trials: the safety run-in cohort of this trial, completed in March 2025, the Phase 1 trial in recurrent ovarian cancer (RAD-18-001, n=21) and the Phase 1/2a trial in colorectal cancer (RAD-18-002, n=47), in which no dose-limiting toxicity was observed at the recommended dose of 7 MBq [1,2].

“These first randomized data are an important milestone for Oncoinvent and for the Radspherin® program,” said Dr Zuzana Jirakova Trnkova, Chief Medical Officer of Oncoinvent. “The safety profile is in line with what we have reported in previous studies, which strengthens our confidence as we move towards the efficacy readout in the spring and readiness for Phase 3. We thank the patients, investigators and site teams who made this possible.”

Recruitment in the phase 2 trial is expected to complete in the first half of 2027. The interim efficacy readout, planned for April 2027, will include close to all randomized patients, of whom approximately 40 will have at least nine months of follow-up.

***

Notes on Safety Terminology

  • Adverse event: An unintended medical event reported by a patient during the trial, regardless of whether it is related to the trial drug.
  • Treatment-emergent adverse events: Any unintended medical event that began or worsened after the patient received the first dose of the trial drug, whether or not it was caused by the drug.
  • Serious treatment-emergent adverse events: A major medical event (such as hospitalization or a life-threatening condition) that began or worsened after treatment started, regardless of whether it was linked to the trial drug.

***

[1] Wang, Yun, et al. “First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer.” Gynecologic Oncology 204 (2026): 158-164.

[2] Larsen, Stein Gunnar, et al. “First experience with 224Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study).” Frontiers in medicine 10 (2023): 1070362.

For further information, please contact:
Oncoinvent

Oystein Soug, Chief Executive Officer
IR@oncoinvent.com

Optimum Strategic Communications
Zoe Bolt, Katherine Bliss, Henry Williams
+44 (0) 203 882 9621

oncoinvent@optimumcomms.com

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Renate Birkeli, Director Investor Relations, on the date and at the time set out above, on behalf of the Company.



About the Phase 2 trial

RAD-18-003 (NCT06504147) is a randomized, open-label, multicenter Phase 2 trial in women with primary advanced, HRD-negative ovarian cancer who receive neoadjuvant chemotherapy followed by interval cytoreductive surgery with complete resection. After a six-patient safety run-in, patients are randomized 2:1 to a single intraperitoneal dose of Radspherin® (7 MBq) after surgery plus standard of care, or standard of care alone. The primary endpoint is progression-free survival. The trial is recruiting at 11 sites in Europe and the United States.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is intended to be broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile demonstrated in clinical trials, and seamless integration into existing surgical workflows. Oncoinvent's product is easy to use and has shown success in avoiding systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.

Data from two trials in ovarian (Phase 1) and colorectal (Phase 1/2a) cancers are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim efficacy data from the ongoing, randomized, controlled Phase 2 ovarian cancer trial are expected in April 2027.

With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).

Radspherin® is an investigational product that is not yet approved for commercial use. This announcement is intended solely to provide information and not to promote or provide medical advice regarding Radspherin® or any other product or medical condition.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Oncoinvent's plans, estimates, or expectations will be achieved. These forward-looking statements represent Oncoinvent's expectations as of the date of this press release, and Oncoinvent disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers.

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.

Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.